

17157

Please type a plus sign (+) inside this box → 

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>		<b>Attorney Docket No.</b> 05213-3001 (43170-295490)
		<b>Inventors</b> ROBERT J. D'AMATO and M. JUDAH FOLKMAN
		<b>Title</b> ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS
		<b>Express Mail Label No.</b> EV334681805US

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

19270 U.S. PTO  
10789471

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO:</b> Commissioner for Patents Mailstop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i></p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification <b>[Total Pages</b> 18 <b>]</b> <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross Reference to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (<i>if filed</i>)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) <b>[Total Sheets</b> 3 <b>]</b></p> <p>5. Oath or Declaration <b>[Total Pages</b> 2 <b>]</b></p> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> Newly executed (original or copy)</li> <li>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63 (d)) <i>(for a continuation/divisional with Box 18 completed)</i></li> <li>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li> </ul> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p>		<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (<i>if applicable, all necessary</i>)</p> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer Readable Form (CRF)</li> <li>b. Specification Sequence Listing on:           <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</li> <li>ii. <input type="checkbox"/> paper</li> </ul> </li> <li>c. <input type="checkbox"/> Statements verifying identity of above copies</li> </ul>
<b>ACCOMPANYING APPLICATIONS PARTS</b>		
<p>9. <input type="checkbox"/> Assignment:</p> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</li> <li>b. <input type="checkbox"/> Assignment is of record in parent application No.</li> </ul> <p>10. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input type="checkbox"/> Power of Attorney (<i>when there is an assignee</i>)</p> <p>11. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)</p> <p>12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (<i>Should be specifically itemized</i>)</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (<i>if foreign priority is claimed</i>)</p> <p>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>17. <input type="checkbox"/> Other _____</p>		

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation     Divisional     Continuation-in-part (CIP)

of prior application No: 10/077,142/February 15, 2002

Prior application information: Examiner Radio

Group / Art Unit: 1616

Recite complete dependency back to first parent application: This application is a continuation-in-part of U.S. Patent Application Serial No. 10/077,142, filed February 15, 2002; which is a continuation of U.S. Patent Application Serial No. 09/243,158 filed February 2, 1999, which is a divisional of U.S. Application Serial No. 08/838,699 filed April 25, 1997, now U.S. Patent No. 5,892,069, which is a divisional of U.S. Application Serial No. 08/571,265 filed December 12, 1995, now U.S. Patent No. 5,661,143, which is a continuation of Application No. 08/102,767, filed August 6, 1993, now U.S. Patent No. 5,504,074.

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

#### 17. CORRESPONDENCE ADDRESS

Customer Number

23370

Name (Print/Type)	Robert E. Richards	Registration No. (Attorney/Agent)	29,105
Signature			Date
			February 27, 2004

022704

17157  
FEE TRANSMITTAL  
U.S. PATENT AND TRADEMARK OFFICE

Attorney Docket No. 05213-3001 (43170-295490)

This sheet accompanies a patent application transmittal for the following application:

Inventor(s): ROBERT J. D'AMATO and M. JUDAH FOLKMAN  
 Filing Date: February 24, 2004  
 Title: ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS

The filing fee is calculated as shown below:

## 1. FILING FEE:

FOR:	SMALL ENTITY		LARGE ENTITY	
	FEE	FEE PAID	FEE	FEE PAID
<input checked="" type="checkbox"/> UTILITY FILING FEE	\$385		\$770	770
<input type="checkbox"/> DESIGN FILING FEE	\$170		\$340	
<input type="checkbox"/> PLANT FILING FEE	\$265		\$530	
<input type="checkbox"/> REISSUE FILING FEE	\$385		\$770	
<input type="checkbox"/> PROVISIONAL FILING FEE	\$80		\$160	
	SUBTOTAL (1)	\$		\$770

## 2. CLAIMS:

FOR:	SMALL ENTITY		LARGE ENTITY	
	RATE	FEE	RATE	FEE
TOTAL CLAIMS	7 - 20 =	0	x 9 =	
INDEP. CLAIMS	1 - 3 =	0	x 43 =	
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED	+145 =		+290 =	
	SUBTOTAL (2)	\$		\$0

## 3. ADDITIONAL FEES:


FOR:	SMALL ENTITY		LARGE ENTITY	
	FEE	FEE PAID	FEE	FEE PAID
<input type="checkbox"/> LATE FILING, FEE OR OATH	\$65		\$130	
<input type="checkbox"/> NON-ENGLISH SPECIFICATION	\$130		\$130	
<input type="checkbox"/> OTHER				
	SUBTOTAL (3)	\$		\$0

**TOTAL FILING FEES: \$770**

A check is enclosed for the total amount: \$770

 Charge any additional fees required under 37 C.F.R. 1.16 or 1.17 to Deposit Account 11-0855.

KILPATRICK STOCKTON LLP  
 1100 Peachtree Street  
 Suite 2800  
 Atlanta, Georgia 30309-4530  
 Telephone: 404-815-6500

By:   
 Robert E. Richards, Attorney for Applicant  
 Reg. No. 29,105

Date: 2-27-04